|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 157.30 EUR | +1.09% |
|
+13.33% | +32.18% |
| 02-13 | Genfit to Receive $20 Million Milestone Payment Linked to Sales of Ipsen's Iqirvo | MT |
| 02-13 | Ipsen Remains in the Green with UBS Support |  |
Business description: Ipsen
- oncology (73.7%);
- neuroscience (20.6%);
- rare diseases (5.7%).
At the end of 2024, the group had 4 research and development centres located in France, the United Kingdom, the United States and China, and 4 manufacturing sites worldwide.
Net sales are distributed geographically as follows: Europe (39.3%), North America (34.3%) and other (26.4%).
Number of employees: 5,358
Sales by Activity: Ipsen
| Fiscal Period: December | 2020 (EUR) | 2021 (EUR) | 2022 (EUR) | 2023 (EUR) | 2024 (EUR) |
|---|---|---|---|---|---|
Specialty Care | 2.45B | 2.75B | 3.16B | 3.31B | 3.57B |
Consumer Healthcare | 233M | 250M | - | - | - |
Geographical breakdown of sales: Ipsen
| Fiscal Period: December | 2020 (EUR) | 2021 (EUR) | 2022 (EUR) | 2023 (EUR) | 2024 (EUR) |
|---|---|---|---|---|---|
Europe | - | - | 1.24B | 1.26B | 1.34B |
North America | 858M | 916M | 1.03B | 1.04B | 1.17B |
Rest of World | - | - | 756M | 829M | 897M |
Eastern Europe | 219M | 261M | - | - | - |
Other Rest of The World | 216M | 260M | - | - | - |
Asia | 193M | 252M | - | - | - |
Others Europe | 282M | 295M | - | - | - |
U.K. | 116M | 116M | - | - | - |
Germany | 191M | 199M | - | - | - |
Italy | 109M | 130M | - | - | - |
Spain | 111M | 125M | - | - | - |
France | 297M | 314M | - | - | - |
Executive Committee: Ipsen
| Manager | Title | Age | Since |
|---|---|---|---|
David Loew
CEO | Chief Executive Officer | 58 | 01/07/2020 |
| Chief Executive Officer | 56 | 01/01/2020 | |
| Chief Tech/Sci/R&D Officer | 59 | 22/09/2023 | |
Sandra Silvestri
CTO | Chief Tech/Sci/R&D Officer | 52 | 05/05/2023 |
Aidan Murphy
CTO | Chief Tech/Sci/R&D Officer | 59 | 01/01/2018 |
Composition of the Board of Directors: Ipsen
| Director | Title | Age | Since |
|---|---|---|---|
Antoine Flochel
BRD | Director/Board Member | 61 | 30/08/2005 |
| Chairman | 67 | 22/11/2010 | |
Carol Xueref
BRD | Director/Board Member | 69 | 01/06/2012 |
| Director/Board Member | 56 | 01/06/2020 | |
Michèle Ollier
BRD | Director/Board Member | 67 | 27/05/2015 |
Margaret Liu
BRD | Director/Board Member | 68 | 07/06/2017 |
Piet Wigerinck
BRD | Director/Board Member | 60 | 01/05/2018 |
David Loew
BRD | Director/Board Member | 58 | 01/07/2020 |
| Director/Board Member | 46 | 06/11/2020 | |
Karen Witts
BRD | Director/Board Member | 63 | 21/01/2022 |
Holdings: Ipsen
Company details: Ipsen
Group companies: Ipsen
| Name | Category and Sector |
|---|---|
Socapharma SAS | |
Ipsen Pharma Biotech SAS
 Ipsen Pharma Biotech SAS Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products |
Pharmaceuticals: Major
|
Ipsen Pharma SAS
 Ipsen Pharma SAS Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products |
Pharmaceuticals: Major
|
Ipsen Pharma SAS
Ipsen Pharma SAS Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products |
Pharmaceuticals: Major
|
Other Pharmaceuticals
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.09% | +13.33% | +40.57% | +46.05% | 15.11B | |
| -1.50% | +0.53% | +19.06% | +210.77% | 926B | |
| +0.68% | +1.71% | +58.07% | +52.75% | 586B | |
| -1.78% | +3.54% | +16.55% | +51.16% | 412B | |
| +0.03% | +3.50% | +25.23% | +32.27% | 382B | |
| +0.13% | +4.89% | +31.85% | +35.31% | 326B | |
| -0.78% | +3.48% | +32.45% | +58.65% | 317B | |
| +0.07% | +1.97% | +46.07% | +11.08% | 302B | |
| +0.45% | +1.50% | -46.97% | -36.86% | 218B | |
| +1.71% | +3.59% | +29.69% | +57.87% | 201B | |
| Average | +0.21% | +4.14% | +25.26% | +51.91% | 368.43B | |
| Weighted average by Cap. | +0.12% | +2.82% | +26.88% | +80.65% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- IPN Stock
- Company Ipsen
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition